47.12 +0.27 (0.58%)
Pre-Market: 4:17AM EDT
|Bid||46.68 x 900|
|Ask||46.99 x 2900|
|Day's Range||46.59 - 47.23|
|52 Week Range||44.30 - 63.69|
|Beta (3Y Monthly)||0.85|
|PE Ratio (TTM)||14.92|
|Earnings Date||Jul 24, 2019 - Jul 29, 2019|
|Forward Dividend & Yield||1.64 (3.53%)|
|1y Target Est||57.30|
Roche (RHHBY) gains an FDA nod for the sNDA of its leukemia drug, Venclexta, in combination with Gazyva for the treatment of previously untreated chronic lymphocytic leukemia.
New data on Opdivo plus Yervoy in patients with advanced hepatocellular carcinoma and in melanoma patients with symptomatic brain metastases
In the Lightning Round of Wednesday's Mad Money program, Jim Cramer favored Bristol-Myers Squibb Co. which has been in a downtrend from August," Cramer told viewers. In the daily bar chart of BMY, below, we can identify three trends in the past twelve months.
PRESS RELEASE : 16 May 2019, 07:00 CEST Idylla(TM) MSI Performance Study Selected for Publication at ASCO Conference Mechelen, Belgium, 16 May 2019 - Biocartis Group NV (the `Company` or `Biocartis`), ...
Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets approval in the United States.
Pharmaceutical giant Gilead Sciences engaged in a "long-running scheme" to block generic competition of its combination drug "cocktails" to treat HIV. The complaint, filed in the U.S. District Court in San Francisco, names drugmakers Bristol-Myers Squibb and Johnson & Johnson subsidiary Janssen Pharmaceuticals as co-defendants. The plaintiffs in the suit claim that Gilead's actions caused the cost of the life-saving treatment to rise.
This is a club for stocks that have hardly budged from where they were a month ago, and a year ago. Such stocks are often neglected by investors and sometimes by analysts too. Warning! GuruFocus has detected 3 Warning Signs with FLR.
Zacks.com featured highlights include: BlackRock, Northrop, Progressive, Interpublic Group and Bristol-Myers
Two-time Emmy Award winner Sterling K. Brown (This Is Us, Black Panther) is partnering with Bristol-Myers Squibb on a series designed to illuminate the triumphs and challenges of life after a cancer diagnosis. Survivorship Today: What It’s Like to Live with Cancer explores the stories of people who have experienced lasting physical, emotional and social effects from cancer to build greater understanding of, and draw attention to, survivorship-related issues. Today, more people who have been diagnosed with cancer are able to live with the disease than ever before.
Bristol-Myers Squibb Company will take part in a fireside chat at the UBS Global Healthcare Conference on Tuesday, May 21, 2019, in New York. Giovanni Caforio, M.D., chairman and chief executive officer will answer questions at 2:30 p.m.
Bristol-Myers Squibb's (BMY) move to raise close to $20 billion in debt to acquire Celgene (CELG) looks dangerous, but years from now it may be considered a savvy move. True, the huge aggregate number of $58 billion in combined debt between the two companies certainly doesn't look all that flattering, especially in the context of threats by all three credit rating agencies - Moody's, Fitch and S&P Global Ratings - to downgrade the company's credit rating. The ratings agencies correctly cite total debt at 4x earnings, and that makes the corporate bond markets justifiably jittery.
AVEO Pharmaceuticals (AVEO) discourages investors in Q1 with wider-than-expected loss as well as a revenue miss. Also, Fotivda NDA gets delayed as the FDA was dissatisfied with the OS data.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
Nektar's (NKTR) earnings and sales beat estimates in the first quarter. The company is progressing well with its pipeline candidates.
The spending by the industry’s main trade group and seven key drugmakers has climbed to a level not seen in a decade.
Zacks.com featured highlights include: Exantas Capital, Lamb Weston, Bristol-Myers Squibb, Amedisys and Computer Programs and Systems
Bristol-Myers Squibb said the Phase 3 study dubbed CheckMate-498 that evaluated Opdivo plus radiation versus temozolomide plus radiation in patients with newly diagnosed O6-methylguanine-DNA methyltransferase-unmethylated glioblastoma multiforme — a form of brain tumor — did not meet the primary endpoint of overall survival at final analysis.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
Bristol-Myers Squibb Co said on Thursday its immunotherapy Opdivo failed to meet the main goal of a late-stage trial testing it in patients with an aggressive form of tumor that affects the brain or the spine. Opdivo, used in combination with radiation therapy, failed to extend survival in patients with glioblastoma multiforme (GBM), when compared with the chemotherapy temozolomide and radiation therapy. GBM is the most common type of tumor that forms in the nervous system.
Yahoo Finance's Alexis Christoforous and Brian Sozzi talk to former Aetna CEO and friend of Uber board member Ursula Burns about the current state of healthcare, the anticipation ahead of the Uber IPO and overall stocks that are gaining attention in the market.